Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso

Stock News

Yesterday

Nomura has issued a research report assigning a target price of HK$138.29 and a "Buy" rating to Akeso (09926).

Nomura noted that before the Hong Kong stock market opened on September 29, Akeso and its overseas partner Summit Therapeutics (SMMT.US) announced that Summit had secured a US$2 billion strategic investment from AstraZeneca (AZN.US).

This US$2 billion investment by AstraZeneca in Summit's convertible preferred stock is equivalent to approximately 12% equity in Summit's common stock (10.6% on a diluted basis).

The two parties will also collaborate to evaluate sonesitatug vedotin, a CLDN 18.2 ADC drug licensed by AstraZeneca from a joint venture formed by Keymed Biosciences (02162) and Lepu Biopharma (02157), alongside ivonescimab.

The bank believes this is positive news for the global development of ivonescimab, which is a core component of Akeso's value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1172902077"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172902077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172902077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172902077","market":"us","top_or_hot":-1,"title":"Nomura Assigns HK$138.29 Target Price and \"Buy\" Rating to Akeso","media":"Stock News","content":"<p>Nomura has issued a research report assigning a target price of HK$138.29 and a \"Buy\" rating to <b>Akeso</b> (<b>09926</b>).<br><br>Nomura noted that before the Hong Kong stock market opened on September 29, <b>Akeso</b> and its overseas partner <b>Summit Therapeutics</b> (<b>SMMT.US</b>) announced that Summit had secured a US$2 billion strategic investment from <b>AstraZeneca</b> (<b>AZN.US</b>).<br><br>This US$2 billion investment by AstraZeneca in Summit's convertible preferred stock is equivalent to approximately 12% equity in Summit's common stock (10.6% on a diluted basis).<br><br>The two parties will also collaborate to evaluate sonesitatug vedotin, a CLDN 18.2 ADC drug licensed by AstraZeneca from a joint venture formed by <b>Keymed Biosciences</b> (<b>02162</b>) and <b>Lepu Biopharma</b> (<b>02157</b>), alongside ivonescimab.<br><br>The bank believes this is positive news for the global development of ivonescimab, which is a core component of <b>Akeso</b>'s value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nomura Assigns HK$138.29 Target Price and \"Buy\" Rating to Akeso</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNomura Assigns HK$138.29 Target Price and \"Buy\" Rating to Akeso\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-30 15:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nomura has issued a research report assigning a target price of HK$138.29 and a \"Buy\" rating to <b>Akeso</b> (<b>09926</b>).<br><br>Nomura noted that before the Hong Kong stock market opened on September 29, <b>Akeso</b> and its overseas partner <b>Summit Therapeutics</b> (<b>SMMT.US</b>) announced that Summit had secured a US$2 billion strategic investment from <b>AstraZeneca</b> (<b>AZN.US</b>).<br><br>This US$2 billion investment by AstraZeneca in Summit's convertible preferred stock is equivalent to approximately 12% equity in Summit's common stock (10.6% on a diluted basis).<br><br>The two parties will also collaborate to evaluate sonesitatug vedotin, a CLDN 18.2 ADC drug licensed by AstraZeneca from a joint venture formed by <b>Keymed Biosciences</b> (<b>02162</b>) and <b>Lepu Biopharma</b> (<b>02157</b>), alongside ivonescimab.<br><br>The bank believes this is positive news for the global development of ivonescimab, which is a core component of <b>Akeso</b>'s value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348827113.USD","symbol_name":"ALLIANZ RCM CHINA \"AT\" ACC","start_time":0,"source_url":"","article_id":"1172902077","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172902077","pubTimestamp":1790751617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Nomura has issued a research report assigning a target price of HK$138.29 and a \"Buy\" rating to Akeso (09926).Nomura noted that before the Hong Kong stock market opened on September 29, Akeso and its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1161":"生物科技","02157":"乐普生物","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","09926":"康方生物","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1587":"次新股","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","BK1574":"生物医药B类股","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","BK1583":"高瓴概念","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","02162":"康诺亚-B","EWH":"香港ETF-iShares MSCI","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC"},"translate_title":"野村证券给予Akeso 138.29港元目标价和“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1,"KURE":1,"02157":1,"09926":1,"EWH":1},"content_text":"Nomura has issued a research report assigning a target price of HK$138.29 and a \"Buy\" rating to Akeso (09926).Nomura noted that before the Hong Kong stock market opened on September 29, Akeso and its overseas partner Summit Therapeutics (SMMT.US) announced that Summit had secured a US$2 billion strategic investment from AstraZeneca (AZN.US).This US$2 billion investment by AstraZeneca in Summit's convertible preferred stock is equivalent to approximately 12% equity in Summit's common stock (10.6% on a diluted basis).The two parties will also collaborate to evaluate sonesitatug vedotin, a CLDN 18.2 ADC drug licensed by AstraZeneca from a joint venture formed by Keymed Biosciences (02162) and Lepu Biopharma (02157), alongside ivonescimab.The bank believes this is positive news for the global development of ivonescimab, which is a core component of Akeso's value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}